News
CSLLY
77.52
-1.89%
-1.49
Weekly Report: what happened at CSLLY last week (0602-0606)?
Weekly Report · 6d ago
Epic adds Keith from Lockton as Mid-Atlantic president
Reuters · 06/05 06:17
Weekly Report: what happened at CSLLY last week (0526-0530)?
Weekly Report · 06/02 11:13
Weekly Report: what happened at CSLLY last week (0519-0523)?
Weekly Report · 05/26 11:12
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Seeking Alpha · 05/23 13:46
CSL (CMXHF) Receives a Buy from Jarden
TipRanks · 05/20 23:35
Weekly Report: what happened at CSLLY last week (0512-0516)?
Weekly Report · 05/19 11:03
CSL (CMXHF) Gets a Buy from Goldman Sachs
TipRanks · 05/15 01:37
Morgan Stanley Remains a Buy on CSL (CMXHF)
TipRanks · 05/13 00:07
Weekly Report: what happened at CSLLY last week (0505-0509)?
Weekly Report · 05/12 11:04
Aussie shares end flat as miners offset healthcare stocks, Trump comments hit pharma stocks
Reuters · 05/12 06:44
BUZZ-Australia's healthcare stocks drop as Trump plans executive order to cut prescription drug prices
Reuters · 05/12 04:58
Invesco Oppenheimer International Growth Fund Q1 2025 Commentary
Seeking Alpha · 05/11 05:38
Invesco EQV International Equity Fund Q1 2025 Commentary
Seeking Alpha · 05/09 12:40
BUZZ-Australian healthcare stocks at 1-week low on fears of hit to exports to US
Reuters · 05/07 03:28
Weekly Report: what happened at CSLLY last week (0428-0502)?
Weekly Report · 05/05 11:06
Trump administration said to be investing $500M on developing universal vaccines
Seeking Alpha · 05/01 09:12
CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROVAL FOR FILSPARI® IN IGA NEPHROPATHY
Reuters · 04/29 06:01
CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROVAL FOR FILSPARI® IN IGA NEPHROPATHY
Reuters · 04/29 06:01
Weekly Report: what happened at CSLLY last week (0421-0425)?
Weekly Report · 04/28 11:15
More
Webull provides a variety of real-time CSLLY stock news. You can receive the latest news about Csl Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CSLLY
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.